<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The activating mutation FGFR3-R248C in the D2-D3 linker region of fibroblast growth factor receptor 3 leads as germline mutation to the <z:hpo ids='HP_0003811'>neonatal lethal</z:hpo> syndrome thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath> type I (TD1) </plain></SENT>
<SENT sid="1" pm="."><plain>As <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> it has been found in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We introduced into the murine FGFR3 the mutation R242C that is orthologoues to the human mutation R248C </plain></SENT>
<SENT sid="3" pm="."><plain>A strong reduction in binding of the 16 and 18 kDa forms of FGF1 to the mutant receptor was found, highlighting the importance of D2-D3 linker region of FGFR3 in determination of binding affinity to ligands </plain></SENT>
<SENT sid="4" pm="."><plain>Another mutant, G374R, introduced into the murine FGFR3, is orthologoues to the human mutant FGFR3-G380R, and leads to <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> (ACH) </plain></SENT>
<SENT sid="5" pm="."><plain>The binding of the 16 kDa and 18 kDa forms of FGF1 to this mutant receptor was the same as for <z:mp ids='MP_0002169'>wild-type</z:mp> FGFR3 in a cell-free system, but it was reduced in living cells </plain></SENT>
<SENT sid="6" pm="."><plain>The data indicate a minor changes in conformation of FGFR3-G374R receptors at the cell surface that lead to reduced binding to FGF1 </plain></SENT>
</text></document>